Inhibition of invasion and metastasis in oral cancer by targeting urokinase-type plasminogen activator receptor. 2005

Shinichi Nozaki, and Yoshio Endo, and Hirokazu Nakahara, and Kunio Yoshizawa, and Yukari Hashiba, and Shuichi Kawashiri, and Akira Tanaka, and Kiyomasa Nakagawa, and Yudai Matsuoka, and Mikihiko Kogo, and Etsuhide Yamamoto
Department of Oral and Maxillofacial Surgery, Kanazawa University Graduate School of Medical Science, 13-1 Takaramachi, Kanazawa, Ishikawa 920-8641, Japan. snozaki@med.kanazawa-u.ac.jp

There have been reports of strong correlations between poor prognosis in various cancers and concomitant expression of urokinase-type plasminogen activator (uPA) and its surface receptor (uPAR). We and others have previously shown that the uPA system plays a significant role in a subset of head and neck squamous cell carcinoma. In the present study, we found that uPAR is required for invasion and metastasis of highly malignant oral cancer cells (OSC-19). Treating OSC-19 cells with antisense oligonucleotides (AS) targeting uPAR resulted in a dramatic decrease of uPAR mRNA expression. Furthermore, pretreatment with AS or siRNA targeting uPAR inhibited progression of OSC-19 cells in experimental models. These results suggest that overexpression of uPAR increases the invasiveness and metastasis of OSC-19 cells, and that uPAR is a promising therapeutic target for regulation of progression of oral cancer.

UI MeSH Term Description Entries
D009062 Mouth Neoplasms Tumors or cancer of the MOUTH. Cancer of Mouth,Mouth Cancer,Oral Cancer,Oral Neoplasms,Cancer of the Mouth,Neoplasms, Mouth,Neoplasms, Oral,Cancer, Mouth,Cancer, Oral,Cancers, Mouth,Cancers, Oral,Mouth Cancers,Mouth Neoplasm,Neoplasm, Mouth,Neoplasm, Oral,Oral Cancers,Oral Neoplasm
D009361 Neoplasm Invasiveness Ability of neoplasms to infiltrate and actively destroy surrounding tissue. Invasiveness, Neoplasm,Neoplasm Invasion,Invasion, Neoplasm
D011956 Receptors, Cell Surface Cell surface proteins that bind signalling molecules external to the cell with high affinity and convert this extracellular event into one or more intracellular signals that alter the behavior of the target cell (From Alberts, Molecular Biology of the Cell, 2nd ed, pp693-5). Cell surface receptors, unlike enzymes, do not chemically alter their ligands. Cell Surface Receptor,Cell Surface Receptors,Hormone Receptors, Cell Surface,Receptors, Endogenous Substances,Cell Surface Hormone Receptors,Endogenous Substances Receptors,Receptor, Cell Surface,Surface Receptor, Cell
D002294 Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) Carcinoma, Epidermoid,Carcinoma, Planocellular,Carcinoma, Squamous,Squamous Cell Carcinoma,Carcinomas, Epidermoid,Carcinomas, Planocellular,Carcinomas, Squamous,Carcinomas, Squamous Cell,Epidermoid Carcinoma,Epidermoid Carcinomas,Planocellular Carcinoma,Planocellular Carcinomas,Squamous Carcinoma,Squamous Carcinomas,Squamous Cell Carcinomas
D002642 Chick Embryo The developmental entity of a fertilized chicken egg (ZYGOTE). The developmental process begins about 24 h before the egg is laid at the BLASTODISC, a small whitish spot on the surface of the EGG YOLK. After 21 days of incubation, the embryo is fully developed before hatching. Embryo, Chick,Chick Embryos,Embryos, Chick
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D014568 Urokinase-Type Plasminogen Activator A proteolytic enzyme that converts PLASMINOGEN to FIBRINOLYSIN where the preferential cleavage is between ARGININE and VALINE. It was isolated originally from human URINE, but is found in most tissues of most VERTEBRATES. Plasminogen Activator, Urokinase-Type,U-Plasminogen Activator,Urinary Plasminogen Activator,Urokinase,Abbokinase,Kidney Plasminogen Activator,Renokinase,Single-Chain Urokinase-Type Plasminogen Activator,U-PA,Single Chain Urokinase Type Plasminogen Activator,U Plasminogen Activator,Urokinase Type Plasminogen Activator

Related Publications

Shinichi Nozaki, and Yoshio Endo, and Hirokazu Nakahara, and Kunio Yoshizawa, and Yukari Hashiba, and Shuichi Kawashiri, and Akira Tanaka, and Kiyomasa Nakagawa, and Yudai Matsuoka, and Mikihiko Kogo, and Etsuhide Yamamoto
February 2011, Clinical cancer research : an official journal of the American Association for Cancer Research,
Shinichi Nozaki, and Yoshio Endo, and Hirokazu Nakahara, and Kunio Yoshizawa, and Yukari Hashiba, and Shuichi Kawashiri, and Akira Tanaka, and Kiyomasa Nakagawa, and Yudai Matsuoka, and Mikihiko Kogo, and Etsuhide Yamamoto
March 2001, Medicinal research reviews,
Shinichi Nozaki, and Yoshio Endo, and Hirokazu Nakahara, and Kunio Yoshizawa, and Yukari Hashiba, and Shuichi Kawashiri, and Akira Tanaka, and Kiyomasa Nakagawa, and Yudai Matsuoka, and Mikihiko Kogo, and Etsuhide Yamamoto
July 2009, The American journal of pathology,
Shinichi Nozaki, and Yoshio Endo, and Hirokazu Nakahara, and Kunio Yoshizawa, and Yukari Hashiba, and Shuichi Kawashiri, and Akira Tanaka, and Kiyomasa Nakagawa, and Yudai Matsuoka, and Mikihiko Kogo, and Etsuhide Yamamoto
August 2010, Cancer investigation,
Shinichi Nozaki, and Yoshio Endo, and Hirokazu Nakahara, and Kunio Yoshizawa, and Yukari Hashiba, and Shuichi Kawashiri, and Akira Tanaka, and Kiyomasa Nakagawa, and Yudai Matsuoka, and Mikihiko Kogo, and Etsuhide Yamamoto
July 2009, International journal of cancer,
Shinichi Nozaki, and Yoshio Endo, and Hirokazu Nakahara, and Kunio Yoshizawa, and Yukari Hashiba, and Shuichi Kawashiri, and Akira Tanaka, and Kiyomasa Nakagawa, and Yudai Matsuoka, and Mikihiko Kogo, and Etsuhide Yamamoto
March 2013, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Shinichi Nozaki, and Yoshio Endo, and Hirokazu Nakahara, and Kunio Yoshizawa, and Yukari Hashiba, and Shuichi Kawashiri, and Akira Tanaka, and Kiyomasa Nakagawa, and Yudai Matsuoka, and Mikihiko Kogo, and Etsuhide Yamamoto
May 1995, International journal of cancer,
Shinichi Nozaki, and Yoshio Endo, and Hirokazu Nakahara, and Kunio Yoshizawa, and Yukari Hashiba, and Shuichi Kawashiri, and Akira Tanaka, and Kiyomasa Nakagawa, and Yudai Matsuoka, and Mikihiko Kogo, and Etsuhide Yamamoto
August 2017, Scientific reports,
Shinichi Nozaki, and Yoshio Endo, and Hirokazu Nakahara, and Kunio Yoshizawa, and Yukari Hashiba, and Shuichi Kawashiri, and Akira Tanaka, and Kiyomasa Nakagawa, and Yudai Matsuoka, and Mikihiko Kogo, and Etsuhide Yamamoto
December 2011, Oncology reports,
Shinichi Nozaki, and Yoshio Endo, and Hirokazu Nakahara, and Kunio Yoshizawa, and Yukari Hashiba, and Shuichi Kawashiri, and Akira Tanaka, and Kiyomasa Nakagawa, and Yudai Matsuoka, and Mikihiko Kogo, and Etsuhide Yamamoto
July 2017, Oncology letters,
Copied contents to your clipboard!